TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07271667: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Sponsor: Curis, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,032,800

Rescue Site Savings

+$1,339,800

Unlock Full NCT07271667 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07271667 Rescue Dossier →